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Objectives We sought to identify patients with ST-segment elevation myocardial infarction most likely to benefit from drug-
eluting stents (DES), and to evaluate the impact of routine angiographic follow-up on the apparent differences
between stent types.
Background DES might have greatest utility in patients who would benefit most from their antirestenotic properties.
Methods We randomly assigned 3,006 patients with ST-segment elevation myocardial infarction to paclitaxel-eluting stents
(PES) or to bare-metal stents (BMS). Events were assessed at 12 months and 24 months, with a subset undergoing
routine angiographic follow-up at 13 months. Using well-known risk factors for restenosis and target lesion revascular-
ization (TLR), risk groups were formed to examine the absolute differences between PES and BMS.
Results Compared with BMS, PES reduced TLR at 12 months from 7.4% to 4.5% (p  0.003). Insulin-treated diabetes
mellitus (hazard ratio: 3.12), reference vessel diameter 3.0 mm (hazard ratio: 2.89), and lesion length 30
mm (hazard ratio: 2.49) were independent predictors of 12-month TLR after BMS. In patients with 2 or 3 of
these baseline risk factors, PES compared with BMS markedly reduced 12-month TLR (19.8% vs. 8.1%, p 
0.003). In patients with 1 of these risk factors, the 12-month rates of TLR were modestly reduced by PES (7.3%
vs. 4.3%, p  0.02). The 12-month TLR rates were low and similar for both stents in patients with 0 risk factors
(3.3% vs. 3.2%, p  0.93). Routine 13-month angiographic follow-up resulted in a marked increase in TLR proce-
dures (more so with BMS) so that the absolute incremental benefit of PES compared with BMS doubled from
2.9% at 12 months to 6.0% at 24 months, a difference evident in all risk strata.
Conclusions Patients at high risk for TLR after BMS in ST-segment elevation myocardial infarction for whom DES are of great-
est benefit may be identified. Conversely, DES may be of less clinical benefit for patients at lower risk for TLR
after BMS. Routine angiographic follow-up increases the perceived clinical benefits of DES, and must be avoided
to accurately estimate absolute treatment effects. (Harmonizing Outcomes With Revascularization and Stents in
Acute Myocardial Infarction [HORIZONS-AMI]; NCT00433966) (J Am Coll Cardiol 2010;56:1597–604) © 2010
by the American College of Cardiology Foundation
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Lessons From the HORIZONS-AMI Trial November 2, 2010:1597–604Numerous randomized trials have
reported that drug-eluting stents
(DES), compared with bare-metal
stents (BMS), reduce recurrent
ischemia requiring repeat target le-
sion revascularization (TLR) pro-
cedures in patients with evolving
ST-segment elevation myocardial
infarction (STEMI) who are un-
dergoing primary percutaneous
coronary intervention (PCI) (1).
However, most of these studies
enrolled a small to moderate num-
ber of patients, and the perfor-
mance of protocol-specified rou-
tine angiographic follow-up before
or at the time of clinical end point
ssessment may have resulted in the performance of addi-
ional TLR procedures that would not otherwise have
ccurred had standard clinical indications for angiographic
ollow-up been followed (2–6), potentially overestimating
he benefits of DES.
In contrast, in the large-scale, international HORIZONS-
MI (Harmonizing Outcomes With Revascularization and
tents in Acute Myocardial Infarction) trial, the 12-month
enefit of DES compared with BMS was modest (7). This
rial was unique in that angiographic follow-up was planned
t 13 months, only after assessment of the primary 12-
onth clinical end point (8). Two-year follow-up in the
ORIZONS-AMI trial is now completed, permitting an
valuation of the impact of routine angiographic follow-up
n the absolute and relative benefits of DES compared with
MS in STEMI. Moreover, physicians performing primary
CI are routinely faced with the decision of whether to use
ES or BMS, with wide variability reported for DES
tilization in STEMI. We hypothesize that the advantages
f DES compared with BMS (before routine angiographic
ollow-up) would be most apparent for patients at high risk
f clinical recurrence after BMS, whereas DES may offer
inimal or no advantages to patients at low risk of recur-
ence after BMS. Therefore, we examined the 2-year results
rom the HORIZONS-AMI trial to develop selection
riteria for DES versus BMS in STEMI, and to explore the
mpact of routine angiographic follow-up.
ethods
atients and trial design. The trial design and 1-year
esults of the HORIZONS-AMI trial have been previously
escribed (7,8). In brief, 3,602 patients 18 years old
erumo, and Tyco. Dr. Möckel has received consulting and lecture honoraria from The
edicines Company. Dr. Lanksy has received research support from Boston Scientific
nd The Medicines Company. Dr. Mehran reports having received consulting fees from
ristol-Myers Squibb/Sanofi, Medtronic, and The Medicines Company. All other
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
DES  drug-eluting stent(s)
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
RVD  reference vessel
diameter
STEMI  ST-segment
elevation myocardial
infarction
TLR  target lesion
revascularizationt
uthors have reported that they have no relationships to disclose.
Manuscript received August 20, 2010; accepted August 26, 2010.resenting within 12 h of symptom onset with 1 mm
T-segment elevation in 2 contiguous leads, or new left
undle branch block, or true posterior MI were enrolled and
andomly assigned equally to unfractionated heparin plus a
lycoprotein IIb/IIIa inhibitor or to bivalirudin alone.
mergent coronary angiography with left ventriculography
as then performed, followed by randomization of an
dditional 3,006 eligible patients in a 3:1 ratio to the
AXUS Express paclitaxel-eluting stent (PES) versus an
therwise identical Express BMS (both Boston Scientific,
atick, Massachusetts). Anatomic eligibility for stent ran-
omization required a visually estimated reference vessel
iameter (RVD) 2.25 and 4.0 mm, without excessive
ortuosity or severe calcification. Angiographic exclusion
riteria consisted of the following: planned unprotected left
ain stenting; a bifurcation lesion requiring planned stent
mplantation in both the main vessel and side branch;100
m stent length anticipated; infarction due to stent throm-
osis; or anticipated bypass graft surgery within 30 days.
Aspirin, 324 mg chewed or 500 mg intravenously, was
iven in the emergency room, followed by 300 to 325 mg
rally daily during the hospitalization and 75 to 81 mg daily
ndefinitely thereafter. A clopidogrel loading dose (either
00 or 600 mg, at investigator discretion) was administered
efore catheterization, followed by 75 mg orally daily for at
east 6 months (1 year or longer recommended).
linical and angiographic follow-up. Clinical follow-up
as planned at 30 days, 6 months, and 12 months, and then
early for 5 years total. The primary clinical end points of
he stent randomization arm were pre-specified at 12
onths. Routine angiographic follow-up at 13 months
after ascertainment of the primary 12-month clinical end
oints) was pre-specified for 1,800 randomized stent pa-
ients in whom acute stent implantation was successful
diameter stenosis 10%, with TIMI [Thrombolysis In
yocardial Infarction] flow grade 3, and National Health,
ung, and Blood Institute type A or less persistent dissec-
ion) and in whom neither stent thrombosis occurred nor
as bypass graft surgery performed within 30 days. Patients
n the angiographic follow-up cohort with documented
estenosis before 13 months, or with clinically driven an-
iography after 6 months but before 13 months, were also
onsidered to have met the angiographic follow-up
equirement.
tudy end points. The trial was powered to demonstrate
he superiority of PES over BMS for the reduction of
2-month ischemia-driven TLR, and noninferiority be-
ween the 2 stent types for the 12-month composite safety
easure of major adverse cardiovascular events consisting of
eath, reinfarction, stroke, or stent thrombosis (7,8). The
omponent definitions of major adverse cardiovascular
vents have been previously defined (8). TLR was consid-
red ischemia-driven if the target lesion diameter stenosis
as 50% with either a positive functional study, ischemic
lectrocardiographic changes, or symptoms referable to the
arget lesion, or 70% by core laboratory quantitative
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November 2, 2010:1597–604 Lessons From the HORIZONS-AMI Trialoronary analysis in the absence of documented ischemia.
tent thrombosis was defined according to the Academic
esearch Consortium classification (9). An independent
linical events committee blinded to treatment assignment
djudicated all primary end point events using original
ource documents and procedural angiograms. Independent
ore angiographic laboratory analysis was performed by
echnicians blinded to treatment assignment and clinical
utcomes using validated methods (10).
tatistical analysis. Patients were analyzed according to
andomized assignment, regardless of treatment received.
ategorical outcomes were compared by the chi-square test
r Fisher exact test. Continuous variables were compared by
he Wilcoxon rank-sum test. Adverse event analyses were
erformed using time-to-event data, are displayed using
aplan-Meier methodology, and were compared with the
og-rank test.
Numerous prior studies have established that long le-
ions, small vessels, and insulin-treated diabetes mellitus are
mong the most consistent and widely accepted baseline risk
actors for clinical and angiographic restenosis (11–16).
herefore, we created low-, intermediate-, and high-risk
roups for restenosis using 3 variables. We assigned 1 point
o each of 3 conditions: 1) RVD 3.0 mm; 2) lesion length
30 mm; and 3) insulin-treated diabetes. Patients with 0, 1,
nd 2 of these 3 risk factors were defined as being at low,
ntermediate, or high risk for TLR and restenosis, respec-
Baseline Characteristics According to Stent RaTable 1 Baseline Characteristics According
Characteristic B
Clinical features
Age, yrs
Male
Diabetes mellitus
Insulin-treated diabetes mellitus
Hypertension
Hyperlipidemia
Current smoker 388
Symptom onset to balloon, min
Killip class 2–4 60
Renal insufficiency* 107
Angiographic features
Number of lesions treated (mean per patient)
Infarct lesion  left anterior descending 347
Baseline TIMI flow per vessel†
0/1 442
2 117
3 211
Reference vessel diameter, mm†
Reference vessel diameter 3.0, mm† 436
Minimal luminal diameter, mm†
Diameter stenosis, %†
Lesion length, mm†
Total lesion length 30 mm (%)† 104
Values are median (range), n (%), median (IQR), or mean  SD. *D
equation 60 ml/min. †Denotes core laboratory assessment.
BMS  bare-metal stent(s); IQR  interquartile range; PES  paclitaxel-eluively. Outcomes by randomized treatment assignment
PES vs. BMS) were then assessed on the basis of strata of
he risk score. Interaction testing was performed to deter-
ine the effect of low-risk versus high-risk strata on the
ifference in 12-month TLR between BMS and PES.
esults
atients and 1-year outcomes. The baseline features of
he randomized groups were well matched, except that
urrent cigarette use was slightly more frequent among
MS patients, whereas lesion length was greater among
ES patients (Table 1). As previously reported (7), com-
ared with BMS, PES significantly reduced the 12-month
ates of TLR, from 7.4% to 4.5% (p  0.003), with
onsignificant differences in death, reinfarction, and stent
hrombosis (Table 2).
Angiographic follow-up was completed in 1,203 patients,
ncluding 193 patients with recurrent ischemia in whom
ngiographic end point criteria were met before the routine
3-month angiogram, and 1,010 patients in whom a
ollow-up angiogram was performed at 13 months for
rotocol purposes. As previously reported (7), binary angio-
raphic restenosis was present in 76 of 328 lesions (23.2%)
n 293 patients in the BMS group versus 103 of 1,066
esions (9.7%) in 910 patients in the PES group (p 
.0001).
izationent Randomization
 749) PES (n  2,257) p Value
26.0–89.0) 59.9 (30.9, 92.3) 0.26
76.0) 1,738 (77.0) 0.56
15.2) 364/2,256 (16.1) 0.55
4.1) 98/2,256 (4.3) 0.92
51.9) 1,155/2,256 (51.2) 0.73
41.1) 953/2,256 (42.2) 0.59
51.9) 1041/2,246 (46.3) 0.009
, 138) 100 (74–134) 0.92
8.0) 199/2,254 (8.8) 0.50
15.4) 328/2,102 (15.6) 0.88
1.1 0.4) 2,527 (1.1 0.4) 0.12
42.3) 1,008/2,527 (39.9) 0.22
57.4) 1424/2,348 (60.6) 0.11
15.2) 320/2,348 (13.6) 0.28
27.4) 604/2,348 (25.7) 0.36
0.50 2.89 0.51 0.75
58.5) 1,332/2,228 (59.8) 0.65
0.45 0.35 0.45 0.81
15.4 87.6 15.4 0.83
8.8 17.5 10.1 0.006
14.1) 434/2,209 (19.6) 0.0008
baseline creatinine clearance calculated using the Cockcroft-Gaultndomto St
MS (n
59.3 (
569 (
114 (
31 (
389 (
308 (
/748 (
97 (71
/748 (
/696 (
820 (
/820 (
/770 (
/770 (
/770 (
2.90
/741 (
0.35
87.4
16.2
/735 (
enotesting stent(s); TIMI  Thrombolysis In Myocardial Infarction.
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Lessons From the HORIZONS-AMI Trial November 2, 2010:1597–604isk groups for target lesion revascularization. All 3 risk
ariables (lesion length 30 mm, RVD 3.0 mm, and
nsulin-requiring diabetes) were independent correlates of
2-month TLR after BMS (Table 3). Among patients with
, 1, or 2 risk factors, the 12-month rates of TLR with
MS ranged from 3.3% (low risk) to 19.8% (high risk)
ptrend  0.0001). As shown in the top graph of Figure 1,
ES markedly reduced the 12-month rates of TLR in the
atient group at highest risk for TLR after BMS (2 or 3 risk
actors), modestly reduced 12-month TLR in the
ntermediate-risk group (1 risk factor), but did not reduce
LR in the patient group at low risk for TLR after BMS (0
isk factor). Formal interaction testing demonstrated a
ignificant effect of high-risk versus low-risk strata on the
ifference in the 12-month rates of TLR between PES and
MS (p  0.02). PES did significantly reduce the 13-
onth rates of angiographic restenosis in all 3 groups,
egardless of baseline risk for TLR after BMS (Fig. 1B).
The 12-month rates of cardiac death, reinfarction, and
tent thrombosis were higher among patients at high risk for
LR after BMS than among patients at intermediate risk
nd low risk for TLR after BMS (Fig. 2). The rates of
ardiac death, reinfarction, and stent thrombosis at 12
onths were comparable among low and intermediate TLR
isk patients treated with PES versus BMS (Figs. 2A and
B), whereas among patients at high risk for BMS TLR,
he 12-month rates of cardiac death and stent thrombosis
ended to be less with PES, although these differences did
ot reach statistical significance (Fig. 2B).
linical Outcomes at 12 Monthsccording o St nt RandomizationTable 2 Clinical Outco es at 12 MonthsAccording to Stent Randomization
Outcome BMS (n  749) PES (n  2,257) p Value
Ischemia-driven TLR 7.4% (54) 4.5% (100) 0.003
Ischemia-driven TVR 8.8% (64) 5.9% (129) 0.006
Death, all-cause 3.5% (26) 3.5% (78) 0.97
Cardiac 2.7% (20) 2.4% (54) 0.67
Noncardiac 0.8% (6) 1.1% (24) 0.55
Reinfarction 4.5% (33) 3.7% (81) 0.31
Q-wave 1.9% (14) 2.0% (45) 0.83
Non–Q-wave 2.6% (19) 1.8% (39) 0.16
Stent thrombosis, any 3.4% (25) 3.1% (69) 0.72
ARC definite 3.0% (22) 2.7% (59) 0.65
ARC probable 0.4% (3) 0.5% (10) 0.87
alues are presented as Kaplan-Meier estimates (number of events).
ARC  Academic Research Consortium; TLR  target lesion revascularization; TVR  target
essel revascularization; other abbreviations as in Table 1.
ultivariable Predictors of 12-Month Ischemicarget Lesion R vascularization Among Patientsndom zed to Bare-Metal Ste ts
Table 3
Multivariable Predictors of 12-Month Ischemic
Target Lesion Revascularization Among Patients
Randomized to Bare-Metal Stents
Variable HR (95% CI) p Value Weighted Score
Insulin-treated diabetes mellitus 3.12 (1.23–7.87) 0.02 1
Baseline RVD 3.0 mm 2.89 (1.56–5.34) 0.0007 1
Total lesion length 30 mm 2.49 (1.33–4.68) 0.004 1t
odel c-statistic  0.66.
CI  confidence interval; HR  hazard ratio; RVD  reference vessel diameter.-year clinical outcomes. As shown in Figure 3, the
aplan-Meier curves for ischemic TLR favoring PES over
MS spread significantly between 3 months and 6 months,
nd then slightly between 6 months and 12 months.
oincident with the 13-month angiographic follow-up,
owever, there was a sharp increase in ischemic TLR in
oth groups (although more so with BMS), followed by the
urves again becoming parallel between 14 months and 24
onths. Underlying this finding, among the 1,010 patients
ith 1,204 lesions in whom the 13-month angiogram was
erformed for protocol purposes only, binary angiographic
estenosis was present in 132 lesions (11.0%), including 60 of
76 BMS-treated lesions and 72 of 928 PES-treated lesions
21.7% vs. 7.8%, respectively; p  0.0001). As a result, TLR
ithin 30 days of this protocol-based angiogram was per-
ormed in 84 patients (8.3%), including 33 of 239 BMS
atients and 51 of 771 PES patients (13.8% vs. 6.6%, respec-
Figure 1 Rates of 12-Month TLR and
13-Month Angiographic Restenosis
(A) Rates of 12-month ischemic target lesion revascularization (TLR) and (B)
13-month angiographic restenosis in patients randomly allocated to paclitaxel-
eluting stents (red bars) or to bare-metal stents (blue bars) according to the
risk strata for restenosis. CI  confidence interval; HR  hazard ratio; RR 
relative risk.ively; p  0.0004), and rarely thereafter (Fig. 4).
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November 2, 2010:1597–604 Lessons From the HORIZONS-AMI TrialCumulative event rates at 24 months and incremental
vent rates between 12 months and 24 months appear in
able 4. Compared with BMS, the absolute difference (95%
onfidence interval) in TLR favoring PES rose from 2.9%
0.8% to 5.0%) at 12 months to 6.0% (3.1% to 8.8%) at 24
onths, and the hazard ratio for the benefit of PES was
arginally improved (hazard ratio: 0.61 [95% confidence
nterval (CI): 0.44 to 0.84], p  0.003 at 12 months, and
.57 [95% CI: 0.44 to 0.72], p  0.0001 at 24 months).
Finally, Figure 5 shows the rates of ischemic TLR at 24
onths among the randomized PES and BMS stratified in
he low-, intermediate-, and high-risk groups for BMS
LR. Compared with BMS, the absolute benefit of PES
Figure 2 Rates of Cardiac Death,
Reinfarction, and ARC Stent Thrombosis
Rates of cardiac death, reinfarction, and Academic Research Consortium (ARC)
definite or probable stent thrombosis at 12 months among patients randomly
assigned to paclitaxel-eluting stents (red bars) or to bare-metal stents (blue
bars) according to the risk strata for restenosis. (A) Patients at low risk for
restenosis; (B) patients at intermediate risk for restenosis; and (C) patients at
high risk for restenosis.as greater in all 3 groups at 24 months (Fig. 5) compared
ith 12 months (Fig. 1A), and the reductions in TLR at 24
onths with PES were highly significant in the
ntermediate-risk and high-risk strata.
iscussion
he principal findings from this report are that: 1) a simple
isk model incorporating the 3 most widely accepted base-
ine risk factors for restenosis was created that was capable
f differentiating patients at low, intermediate, and high risk
or ischemia-driven TLR within 12 months after BMS
Figure 3 Time-to-Event Curves Through
24 Months for Ischemia-Driven TLR
Time-to-event curves through 24 months for ischemia-driven target lesion revas-
cularization (TLR) among patients randomly assigned to paclitaxel-eluting
stents (red line) or to bare-metal stents (blue line). The vertical dotted line
represents the timing of the primary clinical end point at 12 months. Routine
protocol-driven angiographic follow-up was performed at 13 months in 1,010 of
the 3,006 (33.6%) randomized patients. Abbreviations as in Figure 1.
Figure 4 Landmark Analysis for TLR
From Angiographic Follow-Up
Landmark analysis for the occurrence of target lesion revascularization (TLR)
from the time of protocol-specified routine angiographic follow-up at 13 months
in 1,004 patients. Note that 6 patients who had a previous TLR procedure
were excluded from this cohort. Blue line  bare-metal stent; red line 
paclitaxel-eluting stent.
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Lessons From the HORIZONS-AMI Trial November 2, 2010:1597–604mplantation in STEMI (ranging from 3.3% to 19.8%).
) Among patients at highest risk for restenosis, PES
esulted in a marked reduction in TLR at 12 months.
mong patients at intermediate risk for restenosis, PES
esulted in a modest but significant reduction in 12-month
LR. In contrast, no difference in TLR at 12 months was
resent between PES and BMS in patients at low risk for
estenosis. Compared with the BMS, PES did significantly
educe angiographic restenosis in all 3 risk strata, however.
) The performance of routine angiographic follow-up at 13
onths triggered a sharp incremental increase in the num-
er of TLR procedures compared with the background
vent rate that was occurring before angiography, more so
ith BMS than with PES. 4) As a result, the performance
f routine angiographic follow-up after assessment of the
rimary 12-month clinical end point markedly increased the
pparent absolute clinical benefits of PES, compared with
linical Outcomes at 24 Months According to Stent RandomizationTable 4 Clinical Outcomes at 24 Months According to Stent R
Outcome
Incremental Events Between 12 and 24 M
BMS
(n  749)
PES
(n  2,257)
Ischemia-driven TLR 8.5% (58) 5.4% (113)
Ischemia-driven TVR 8.5% (58) 5.4% (113)
Death, all-cause 1.9% (13) 0.9% (18)
Cardiac 0.6% (4) 0.3% (6)
Noncardiac 1.3% (9) 0.6% (12)
Reinfarction 1.5% (10) 2.3% (48)
Stent thrombosis, any 0.7% (5) 1.1% (23)
ARC definite 0.6% (4) 1.1% (22)
ARC probable 0.1% (1) 0.0% (1)
alues are presented as Kaplan-Meier estimates (number of events).
Abbreviations as in Tables 1 and 2.
Figure 5 Rates of 24-Month Ischemic TLR
Rates of 24-month ischemic target lesion revascularization (TLR) for patients
randomly allocated to either paclitaxel-eluting stents (red bars) or bare-metal
stents (blue bars) according to the risk strata for restenosis. Abbreviations as
in Figure 1.rMS, at the 2-year time point, with differences apparent in
ll 3 risk groups.
If accurate assessments of novel therapies are to be
btained, estimates of the treatment effect must be exam-
ned under real-life conditions. Randomized trials may
ncorporate artificial study processes that may insidiously
ffect clinical event rates (2–6). In this regard, a meta-
nalysis of 11 randomized trials (3,607 total patients) of
ES versus BMS in STEMI demonstrated a mean 7.6%
eduction in target vessel revascularization with DES at 12
onths (5.0% vs. 12.6%, respectively; p  0.0001) (1).
owever, to characterize the vascular responses of the
ifferent stent types, routine angiographic follow-up was
erformed before assessment of the clinical end point in 8 of
hese 11 studies (1), likely increasing the absolute if not the
elative benefit of DES by triggering TLR procedures in
symptomatic patients who otherwise would not have un-
ergone angiography (the “oculostenotic reflex”) (2–6).
The HORIZONS-AMI study is the largest prospective,
andomized, controlled trial of primary stenting in STEMI,
nd to our knowledge the first large-scale trial in any setting
o intentionally schedule angiographic follow-up only after
ssessment of the primary clinical end point (7), allowing an
ccurate assessment of the treatment effect of DES in
TEMI. In the HORIZONS-AMI trial, the absolute
ates of clinically-driven TLR in both the BMS and PES
rms at 12 months (7.4% and 4.5%, respectively), as well
s the 2.9% difference favoring PES, were substantially
ower than those reported from prior studies in which
outine angiographic follow-up was common (1), al-
hough they were comparable to the 1-year results from
he PASSION (Paclitaxel-Eluting Stent Versus Conven-
ional Stent in Myocardial Infarction With ST-Segment
levation) trial, in which routine angiographic follow-up
as not performed after randomization of 619 STEMI
atients to PES or to BMS (17).
Of note, as restenosis was more common with BMS than
ES (even in asymptomatic patients), protocol-mandated
ization
s Cumulative Events Between 0 and 24 Months
Value
BMS
(n  749)
PES
(n  2,257) p Value
.003 14.2% (101) 8.3% (178) 0.0001
.003 16.6% (118) 11.0% (236) 0.0001
.03 5.3% (39) 4.3% (96) 0.27
.26 3.3% (24) 2.7% (60) 0.43
.053 2.2% (15) 1.7% (36) 0.44
.19 6.0% (43) 5.7% (123) 0.74
.41 4.1% (30) 4.1% (90) 0.99
.27 3.6% (26) 3.7% (79) 0.97
.41 0.6% (4) 0.5% (11) 0.88andom
onth
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November 2, 2010:1597–604 Lessons From the HORIZONS-AMI Trialtudy triggered a greater proximate increase in TLR proce-
ures in the BMS arm than in the PES arm, so that the
bsolute benefit of PES compared with BMS more than
oubled from 1 to 2 years (2.9% vs. 6.0%). As a result, the
-year estimates of PES clinical efficacy were likely inflated
y this study-specific process, regardless of the baseline risk
or TLR after BMS. In contrast, without angiographic
ollow-up in the PASSION study, the absolute benefit of
ES compared with BMS in reducing TLR was stable
etween 1 and 2 years (2.5% vs. 3.2%, respectively) (17,18).
Moreover, 13-month routine angiographic follow-up was
erformed in only 33.6% of the HORIZONS-AMI trial
tent-randomized patients. The results would have been
ven more skewed had routine angiographic follow-up been
erformed in a greater percentage of study participants. As
een in Figure 4, had all patients undergone routine angio-
raphic follow-up (rather than only 33.6%), the absolute
ncrease in TLR favoring PES over BMS from 1 to 2 years
ight have increased by as much as 7%, rather than the
% observed. These findings serve as a stark illustration
hat routine follow-up angiography must be delayed until
fter the timing of the primary end point in all future
andomized trials, or better yet, performed in a separate
tudy.
Given the incremental cost of DES compared with BMS,
nd ongoing concerns of very late stent thrombosis (19,20),
hich may occur more frequently after DES implantation in
ruptured, thrombotic plaque (21,22), the use of DES in
TEMI should be reserved for patients most likely to
enefit. While this may seem evident, DES utilization rates
n STEMI vary widely by center and operator. In a
onrandomized propensity-controlled study from Ontario,
u et al. (23) reported that DES was associated with
educed rates of target vessel revascularization compared
ith BMS in patients with 2 or 3 risk factors for restenosis,
ncluding diabetes, vessels 3 mm in diameter, and lesions
20 mm in length, but not among lower risk patients. Few
atients in this study had STEMI, however.
The present analysis, drawn from a carefully monitored,
rospective. randomized large-scale international trial thus
onfirms and extends these findings to patients with
TEMI, and to slightly lower risk patients for restenosis. A
imple risk score using the baseline variables of insulin-
reated diabetes, RVD 3.0 mm, and lesion length 30
m effectively differentiated the clinical and angiographic
tility of PES versus BMS after primary PCI. In the 14% of
atients with a risk score of 2, PES resulted in an 11.7%
bsolute reduction in 12-month TLR (number needed to
reat to prevent 1 TLR  8.5), with nonsignificant trends
oward less cardiac death and stent thrombosis. These data
trongly support PES use in this group of patients. In the
4% of patients with 1 risk factor, a modest 3.0% absolute
eduction in 12-month TLR was conferred by PES
ompared with BMS (number needed to treat to prevent
TLR  33.3). Conversely, in the 32% of patients with
risk score of 0, PES and BMS had nearly identical rates cf TLR at 12 months. Compared with BMS, PES
ignificantly reduced angiographic restenosis in all 3 risk
trata, although the absolute reduction in restenosis with
ES varied according to baseline risk (number needed to
reat to prevent 1 restenosis  17.9, 7.2, and 4.3 in the
ow-, intermediate-, and high-risk groups, respectively).
he decision whether to use PES in patients at intermediate
r low risk for TLR after BMS should therefore be
ndividualized, and may involve considerations such as the
ikelihood of prolonged adherence to dual antiplatelet therapy
24), whether future revascularization procedures are antici-
ated, and cost. Of note, by 2 years, the absolute reductions in
LR with PES compared with BMS were more pronounced
n all 3 risk strata, although caution in the interpretation of
he differences between stent types after 1 year is required,
iven the confounding effects from routine angiographic
ollow-up.
tudy limitations. Several limitations of this study deserve
iscussion. First, the present results apply only to patients
ith STEMI, as well as to comparisons of PES versus
MS, and should not be generalized to different clinical
cenarios or other DES with different risk-benefit profiles.
onetheless, the analysis methodology described herein
hould be relevant to these other situations. Second, al-
hough diabetes, lesion length, and RVD have repeatedly
een shown to be predictors of TLR after BMS in numer-
us clinical settings (and were similarly predictive in the
resent study), additional analysis from this and other
atasets are warranted to identify whether additional risk
actors for TLR after BMS in STEMI exist that could
urther strengthen the model. Third, the 13-month rates of
ngiographic follow-up varied in the 3 BMS risk groups,
ikely because of selection bias leading to greater re-study of
atients at higher risk for restenosis. Fourth, while it is
ikely that most patients undergoing 13-month angiography
id so for protocol purposes only, it is possible that
rogressive symptoms developed in a minority between the
2-month primary clinical end point assessment and the
3-month scheduled angiogram; the case report form did
ot make this distinction. Fifth, TLR procedures without
vident ischemia were adjudicated as non–end points by the
linical event adjudication committee. However, a 70%
iameter stenosis by quantitative coronary angiography
equivalent to a 80% to 90% visually estimated stenosis)
as adjudicated as an ischemia-driven TLR because of its
ikelihood to cause an adverse event if untreated. While
his definition is standard among DES studies, this
omplexity further highlights the intricacies of study
nterpretation after performing nonclinically indicated
rocedures such as routine angiographic follow-up. Fi-
ally, even the HORIZONS-AMI study was not pow-
red to detect differences in low-frequency safety end
oints between stent types, such as death and stent
hrombosis, especially within the 3 TLR risk groups
reated.
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hese limitations notwithstanding, the present study pro-
ides important guidance as to which patients might benefit
rom PES rather than BMS in STEMI. In patients at high
isk for TLR after BMS, PES markedly reduces clinical and
ngiographic restenosis, with no safety concerns apparent.
onversely, the selection of stent type for patients at
ntermediate and low risk for TLR after BMS should be
ndividualized, but may be considered as long as long-term
ual antiplatelet therapy compliance is likely. Finally, rou-
ine angiographic follow-up in stent studies distorts the
ccurate assessment of clinical treatment effects and must be
voided in future randomized trials.
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